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BACKGROUND: Inflammation affects brain after stroke with main functions to rapidly eliminate the source of the disturbance, remove damaged tissue 
and then restore tissue homeostasis. High sensitive C-reactive 
protein (hsCRP) is a sensitive marker of inflammation and 
tissue injury in the arterial wall, while fractalkine is a distinct 
chemokine that promotes inflammatory signaling after 
neuronal death on ischemic stroke. We aim to investigate 
the association of fractalkine with hsCRP as a marker of 
inflammation in ischemic stroke patients.
METHODS: This study was designed as a cross-sectional 
study. Soon after patients with ischemic stroke admitted 
to hospital, plasma fractalkine and hsCRP concentrations 
were assesed. Subjects had to be at least 30 years old and 
maximum 30 days of stroke onset. High inflammation was 
defined as hsCRP value >3 mg/L.
Abstract
Introduction
Stroke is one of the non-communicable diseases (NCD), 
a group of diseases causing the death, leading of second 
ranked in the world after coronary heart disease. It was 
estimated that about 16 million people affected by the first 
stroke each year and 5.7 million people died of stroke.(1) 
Among all types of stroke, ischemic stroke has been found 
to take place 85% of stroke incidence. 
 Inflammation involved in ischemia cascade has 
important role in the course of stroke.(2) After ischemic 
RESULTS: High fractalkine levels were found on 24 
ischemic stroke patients (49%) and mean of fractalkine 0.719 
ng/mL on patients with stroke onset <7 days was higher than 
patients with stroke onset 7-30 days. Low fractalkine levels 
(<0.527 ng/mL) were found on ischemic stroke patients 
with onset 7-30 days accompanied by high inflammation 
(hsCRP >3 mg/L), but no significant correlation between 
fractalkine and hsCRP (p=0.613).
CONCLUSION: High inflammation and low plasma 
fractalkine profile was found after 7 days of onset in 
ischemic stroke patients. No significant correlation between 
fractalkine and hsCRP in ischemic stroke patients.
KEYWORDS: CRP, fractalkine, inflammation, ischemic 
stroke
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stroke, inflammatory process affected the brain and 
immune cells such as neutrophils and macrophages. 
Inflammatory process started from the intravascular 
compartment immediately after the occlusion, followed by 
hypoxia, increase of shear stress and production of reactive 
oxygen species (ROS), thereby activating the coagulation 
cascade that led to activation of complement, platelet, 
and endothelial cells. Usually referred as post-ischemic 
inflammation, this process is characterized by a sequence 
of events involving brain, blood vessels, circulating blood 
and lymphoid organs.(3) Meanwhile, in the perivascular 
space, microglia and perifer macrophages, then released the 
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peripheral mediators of pro-inflammatory that contributed 
to the blood-brain barrier damage, including interleukin 
(IL)-6, which stimulate the synthesis of C-reactive protein 
(CRP).(3,4)
 High sensitive CRP (hsCRP) is an acute phase 
protein which sensitively increase on inflammatory process 
and tissue injury in the arterial wall.(5,6) Healthy person 
normally has a median CRP concentration of approximately 
1 mg/L, while during tissue injury, inflammation or infection 
it tends to undergo 100-fold or more increase. Elevated 
plasma CRP levels have been demonstrated to predict 
the risk of future ischemic stroke and  transient ischemic 
attack (TIA) in the elderly. Studies have shown a very early 
increase (within 3 hours) in patients with acute stroke with 
or without infection, and are an independent predictor of 
survival or non-fatal vascular event after ischemic stroke.(7)
 Chemokines are a family of cytokines or signaling 
proteins secreted by cells that form a chemical gradient 
which guides migration of inflammatory cells to the site of 
injury. Fractalkine is a structurally distinct chemokine, the 
only chemokine with the CX3C motif (CX3CL1), exists in 
both a membrane bound and soluble form. In its membrane 
bound form, CX3CL1 serves as an adhesion molecule 
for leukocytes, in its soluble form, it serves as a potent 
chemoattractant for them.(8,9,10) 
 Fractalkine is expressed constitutively in neurons 
and suppressed microglial activation through its microglial 
chemokine with the CX3C motif receptor 1 (CX3CR1) 
which expressed by monocytes, natural killer cells, 
T-lymphocytes, macrophages and microglia. After neuronal 
death, loss of cell-to-cell interaction between neurons and 
microglia, which are kept quiescent in the normal state 
by contact with neurons, also promotes inflammatory 
signaling.(11) Recently, fractalkine has become notable 
in stroke research, primarily in animal models and in in 
vitro studies. The roles of fractalkine in ischemic stroke 
patients is not yet sufficiently investigated and whether 
fractalkine adopts neuroprotective or neurotoxic functions 
remains controversial. We aim to investigate the association 
of fractalkine with hsCRP as a marker of inflammation in 
ischemic stroke patients.
Subjects had to be at least 30 years old and maximum 30 
days of onset stroke. Ischemic stroke was defined according 
to the American Heart Association/American Stroke 
Association (AHA/ASA) as an episode of neurological 
dysfunction caused by focal cerebral, spinal, or retinal 
infarction. Cerebral infarction was diagnosed on the basis 
of history, neurological examination, and brain magnetic 
resonance imaging (MRI). All subtypes of ischemic 
stroke were included. Subjects with ongoing therapy for 
malignancy, known history of brain tumor, and those taking 
immunomodulatory drugs were excluded. Blood was drawn 
as soon as possible when patients admitted to hospital. 
The study was approved by ethics committee of Faculty 
of Medicine, Hasanuddin University, Makassar, Indonesia 
(approval number: UH14110581). 
Subjects Characteristics and Biomarker Assessment
Baseline clinical information was extracted from the 
medical records. Subjects’ demographic and cardiovascular 
risk factors such as hypertension, diabetes mellitus, and 
lipid dysregulation were obtained. Serum hsCRP level 
was estimated by Immulite chemistry system by Prodia 
Clinical Laboratory using chemiluminescent immunometric 
methods. High sensitivity CRP levels was universally 
standardised and accept a value above 3 mg/L as high 
inflammation.(12) Fractalkine levels was determined in 
ethylenediaminetetraacetic acid (EDTA) plasma using 
enzyme-linked immunosorbent assay (ELISA) kits (R&D 
Systems, Inc., Minneapolis, MN, USA). The sensitivity of 
fractalkine assay was 0.018 ng/mL. 
Statistical Analysis
Statistical analysis was performed using the Statistical 
Package for Social Sciences (SPSS 16.0, SPSS Production 
Facility, Chicago, Illinois, USA). Normality of data 
distribution was assessed using Shapiro-Wilk test. The 
non-parametric Spearman rank correlation test was used 
to investigate the relationship between concentrations of 
fractalkine and hsCRP. In  all statistical analyses, two-sided 
p values of 0.05 were considered significant.
Methods Results
Research Subjects
This study was designed as cross sectional study of ischemic 
stroke patients in The Gatot Subroto Army Central Hospital 
Jakarta, from February 2015 through September 2015. 
In total, 49 patients were recruited voluntarily in our study 
during eight months period. The age mean of total subjects 
was 57 years (range, 38-76 years). For further clinical data 
and risk factor see Table 1. Normality test using Shapiro-
Wilk showed that hsCRP and fractalkine didn’t have a 
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normal distribution (p<0.05). Based on 3 mg/L as the cut 
off point for hsCRP, we found 18 patients (36.7%) with low 
inflammation (hsCRP <3 mg/L) and 31 patients (63.3%) 
with high inflammation (hsCRP ≥3 mg/L) in total subjects. 
Fractalkine median levels of total subjects was found 0.527 
ng/mL. Based on this median value, we divided subjects 
into low and high fractalkine group. We found 25 patients 
(51%) were on low fractalkine group and 24 patients (49%) 
were on high fractalkine group. Cross tabulation between 
inflammation group and fractalkine group showed that 
patients with low inflammation have high fractalkine levels 
and patients with high inflammation have low fractalkine 
levels (Figure 1).  
 Previous research have found that fractalkine levels 
decreased on 7 days after stroke onset.(13) Based on this 
finding, we divide subjects into two groups, subjects with 
stroke onset <7 days (A group) and patients with stroke 
onset 7-30 days (B group). In A group, 9 patients (53%) 
have low fractalkine levels, and 8 patients (47%) have high 
fractalkine levels. The same proportion was found in B 
group, 16 patients (50%) have low fractalkine levels and 
16 patients (50%) have high fractalkine levels. Because of 
the same percentage in both group, we tried to calculate the 
mean of fractalkine levels and we found patients on A group 
have higher mean of fractalkine compared to B group (0.719 
ng/mL, 0.585 ng/mL, respectively) (Figure 2), but not 
significant (p=0.395). Supporting this results, we did cross 
tabulation between stroke onset group and hsCRP group and 
we found that patients with stroke onset 7-30 days have high 
inflammation (Figure 3). In this study, we found that subjects 
Discussion
hsCRP, a newer method for CRP assay, has been proved that 
higher levels of hsCRP have a strong predictive value in the 
development of coronary events in the future.(14) It also 
has been reported that low grade inflammation with raised 
levels of  CRP  is  an  independent  risk  factor  for  stroke 
and TIA.(15) CRP levels also have a tendency to increase 
with age, reflecting an increased incidence of subclinical 
pathologic processes.(16) In our study, we found 63.3% of 
total subjects with ischemic stroke have high levels of hsCRP 
(>3 mg/L) and mean of hsCRP in total subjects are 10.5 
mg/L (Table 1). Studies of acute ischemic stroke patients 
have shown varying prevalence and cut off point of hsCRP 
level. Rajput, et al., had found that among acute ischemic 
stroke patients from Pakistan, 132 (88%) had elevated CRP 
(CRP >10 mg/L).(17) Moreover, in a study by Di Napoli, 
et al., in Italy, 95 patients (74.2%) with ischemic stroke 
had high CRP levels (>5 mg/L) at admission.(15) Muir, et 
al., had detected elevated CRP (>10 mg/L) levels in 96 out 
of the 228 (42.1%) patients admitted with acute ischemic 
stroke in the UK.(18) On the other hand, only 22% of stroke 
patients had high CRP (>7 mg/L) levels in a study from 
Netherlands.(19) This variance may be explained partly by 
the different definitions of high CRP in various studies. In 
addition, cohort study of stroke patients with median of 10 
days after stroke onset demonstrated an association between 
higher levels of IL-6, CRP and fibrinogen and an increased 
incidence of recurrent stroke. They found that increase 1 
mg/L of CRP blood levels had a 1.06-fold increase in the 
incidence of recurrent vascular  events.(20) 
 The highest plasma fractalkine in all subjects was 
2.723 ng/mL. Donohue, et al., reported 514 ng/mL (range, 
367-650 ng/mL) as the highest plasma fractalkine by 72 
hours onset, but patients with more severe strokes had 
lower concentrations of plasma fractalkine at day 1 and 7 
compared to control subjects.(13) We found patients with 
stroke onset 7-30 days have mean of fractalkine lower than 
patients with stroke onset <7 days (Figure 2). Other finding 
on their research, higher fractalkine was associated with a 
trend toward decreased hsCRP at multiple time points after 
with stroke onset 7-30 days have higher inflammation than 
subjects with stroke onset <7 days, and subjects with high 
inflammation have low fractalkine levels. Nevertheless, we 
didn’t found a significant correlation between hsCRP and 
fractalkine either in A or B group (Table 2).
Parameters Total Subjects (n = 49)
Gender Female (n, %) 12 (24%)
Male (n, %) 37 (76%)
58 (38-76)
89 (60-159)
144 (100-220)
23 (47%)
35 (71%)
3 (6%)
10.5±16.6
0.635±0.402
Diabetes (n, %)
hsCRP (mg/L, Mean±SD)
Fractalkine (ng/mL, Mean±SD)
*DBP: diastolic blood pressure; SBP: systolic blood pressure
Age (year, Mean, range)
DBP (mmHg, Mean, range) 
SBP (mmHg, Mean, range) 
Hypertension (n, %)
Dyslipoproteinemia (n, %)
Table 1. Baseline characteristics of the study population.
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Figure 2. Mean of fractalkine in stroke onset group.
Figure 3. Profile of inflammation in stroke onset group.
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Figure 1. Profile of fractalkine levels in low and high 
inflammation group. FKN: Fractalkine.
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 The potential contribution of fractalkine to ischemic 
brain injury has been explored in animal models of stroke. 
These studies showed that fractalkine expression was 
upregulated in intact neurons within the penumbra, whereas 
both CX3CL1 and CX3CR1 expression are upregulated 
in the infarcted brain, the  former in neurons and the latter 
in microglia.(22) Mice deficient in CX3CL1 have smaller 
infarct volumes and improved survival after middle cerebral 
artery occlusion.(23) Our study showed high levels of 
fractalkine in ischemic stroke patients with stroke onset < 
7 days, in line to the theory that fractalkine and its receptor 
are upregulated in the infarcted brain. However, not many 
studies have been assesed this chemokine and its role in 
patients with ischemic stroke.
 Fractalkine is constitutively expressed at high levels 
by neurons, mostly in forebrain structures such as the 
hippocampus, amygdala, cerebral cortex, globus pallidus, 
striatum and thalamus, but also in the olfactory bulb, with 
almost no expression in the cerebellum, at the mRNA and 
protein levels in adult mouse in situ.(24) In the central 
nervous system, interaction of fractalkine and its receptor 
regulates the communication among neurons, glia, and 
microglia; that is important in the response to injury; and 
may contribute to neurogenesis. Newly generated cells 
is significantly reduced in the subgranular zone (SGZ) 
of 4 month old CX3CR1KO/KO mice compared with 
CX3CR1KO/+ littermates. Conversely, chronic treatment 
with fractalkine was found to promote neurogenesis in aged 
(22 months  old) but not young (3 months old) or middle-
aged rats (12 months old), while an antagonist of CX3CR1 
produced opposite effects in young, middle-aged and old 
rats.(25) In a follow-up study, comparing CX3CR1KO/KO 
and CX3CR1KO/+ mice with wild-type littermates further 
revealed that adult hippocampal neurogenesis is regulated 
by fractalkine signaling in a gene-dose dependent manner, 
with intermediate levels of neurogenesis measured in the 
heterozygous mice.(24) Although the studied of fractalkine 
and its receptor in neurogenesis are somewhat contradictory, 
these findings was support our results that fractalkine levels 
were upregulated in stroke ischemic patients and decreased 
7 days after stroke onset. As fractalkine levels decreased, 
we found high inflammation on patients with stroke onset 
7-30 days. We presumed that the role of fractalkine changes 
from inflammatory signaling agent in early onset of stroke 
to promoter of neurogenesis in low concentrations at 7 days 
after stroke onset, while post-ischemic inflammation will 
also promote tissue repair in the recovery phase.(26)     
stroke and the associations were significant at 180 days 
after stroke. In our study, we also found that increase of 
hsCRP patients related with decreased of fractalkine levels 
on patients with stroke onset 7-30 days (Figure 2 and 3). 
But we didn’t found any correlation between fractalkine 
and hsCRP in both group of stroke onset (Table 2). This 
finding was similar with the results of Grosse, et al., that no 
association of fractalkine and CRP in stroke patients.(21) 
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In conclusion, we didn’t found a significant association 
between fractalkine and inflammation in stroke ischemic 
patients. We found a high hsCRP level and low plasma 
fractalkine profile after 7 days of onset in ischemic stroke 
patients. 
Conclusion
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